The effect of two different high-flux dialysis membranes on insulin resistance in non-diabetic end-stage renal disease patients

Figures & data

Table 1. Patient characteristics.

Age	61.90 ± 11
Female/male	21/25
Duration of dialysis (months)	78.72 ± 29
Body mass index (kg/m^2)	24.2 ± 4.6
Creatinine (mg/dl)	7.87 ± 1.1
Parathyroid hormone (pg/mL)	301.230 ± 101
Calcium (mg/dl)	8.61 ± 1.2
Phosphorus (mg/dl)	5.252 ± 1.3
Uric acid (mg/dl)	6.352 ± 1.4
Albumin (g/dl)	3.80 ± 0.40
Hemoglobin (g/dl)	10.9 ± 0.80

Table 2. The biochemical difference between PS and PPP treatments.

	PS	PPP	p
Glucose (mg/dl)	97.52 ± 2.183	92.32 ± 2.229	0.006
Insulin (µU/mL)	15.780 ± 1.8132	13.209 ± 1.6665	0.084
HOMA-IR	3.268 ± 0.4643	2.926 ± 0.4476	0.850
Kt/V	1.575 ± 0.535	1.753 ± 0.398	0.002

Notes: PS: Polysulfone; PPP: Polyarylethersulfone, polyvinylpyrrolidone, polyamide; HOMA-IR: Homeostasis Model Assessment-Insulin Resistance; Kt/V: dialysis efficiency value.